Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dornase alfa aerosol in ARDS secondary to COVID-19
2020-001492-33Phase 3Completed
- Sponsor
- Adolphe de Rothschild Foundation Hospital
- Start
- Apr 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of dornase alfa in acute respiratory distress syndrome (ARDS) and coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Adolphe de Rothschild Foundation Hospital. Primary endpoint: Change in PaO2/FiO2 ratio from day 0 to day 7. Started Apr 2020; status: completed.
02
Drugs
dornase alfa
03
Conditions
acute respiratory distress syndrome (ARDS)coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001492-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001492-33.